Cargando…
Clinical Experience With an L-Proline–Stabilized 10 % Intravenous Immunoglobulin (Privigen®): Real-Life Effectiveness and Tolerability
PURPOSE: This retrospective study evaluated the effectiveness and tolerability in clinical practice of an L-proline–stabilized 10 % intravenous immunoglobulin (IVIG; Privigen®) in patients with primary (PID) or secondary immunodeficiency (SID). METHODS: Patients from 6 centers in Europe and the US w...
Autores principales: | Dorsey, Morna J., Ho, Viet, Mabudian, Mohsen, Soler-Palacín, Pere, Domínguez-Pinilla, Nerea, Rishi, Radha, Rishi, Rahul, Wong, Duane, Rojavin, Mikhail, Hubsch, Alphonse, Berger, Melvin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165870/ https://www.ncbi.nlm.nih.gov/pubmed/24981039 http://dx.doi.org/10.1007/s10875-014-0070-z |
Ejemplares similares
-
Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports
por: Shebl, Amgad, et al.
Publicado: (2020) -
Quantitative Evidence of Wear-Off Effect at the End of the Intravenous IgG (IVIG) Dosing Cycle in Primary Immunodeficiency
por: Rojavin, Mikhail A., et al.
Publicado: (2016) -
Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study
por: Wallenhorst, Christopher, et al.
Publicado: (2020) -
Incidence and risk factors for intravenous immunoglobulin‐related hemolysis: A systematic review of clinical trial and real‐world populations
por: Cuesta, Hillary, et al.
Publicado: (2022) -
Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US
por: Martinez, Carlos, et al.
Publicado: (2017)